Equities research analysts expect OpGen Inc (NASDAQ:OPGN) to post ($1.50) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for OpGen’s earnings. OpGen reported earnings per share of ($5.25) during the same quarter last year, which would suggest a positive year over year growth rate of 71.4%. The business is scheduled to announce its next earnings report after the market closes on Thursday, March 15th.
According to Zacks, analysts expect that OpGen will report full year earnings of ($10.00) per share for the current year. For the next year, analysts anticipate that the company will report earnings of ($2.31) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that follow OpGen.
A number of research firms have recently weighed in on OPGN. Zacks Investment Research raised shares of OpGen from a “hold” rating to a “buy” rating and set a $6.25 target price for the company in a research report on Tuesday, November 14th. ValuEngine downgraded shares of OpGen from a “sell” rating to a “strong sell” rating in a report on Thursday, January 25th. Finally, HC Wainwright raised their price objective on shares of OpGen to $9.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th.
OpGen (OPGN) traded up $0.13 during trading on Monday, hitting $2.44. 292,188 shares of the stock were exchanged, compared to its average volume of 509,039. OpGen has a 1 year low of $1.78 and a 1 year high of $31.25. The company has a market cap of $12.00 and a P/E ratio of -0.19. The company has a quick ratio of 1.13, a current ratio of 1.23 and a debt-to-equity ratio of 0.03.
WARNING: “OpGen Inc (OPGN) Expected to Post Earnings of -$1.50 Per Share” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/03/12/opgen-inc-opgn-expected-to-post-earnings-of-1-50-per-share.html.
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.